RED GENOMICS, INC.
TIAS probes—a novel probe-based target enrichment technology for rapid NGS sample preparation that captures and amplifies double-stranded DNA at low temperature without specialized bioinformatics
- Sector
- Medtech
- Headquarters
- Carlsbad, CA
- Total capital
- $591K
- Federal grants
- $591K
- 2 awards · 2023
- Rank in peer group#7 of 23
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 4 pending · first 2024
- Rank in peer group#5 of 23
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Target Insertion Amplification and Sequence (TIAS): A novel targeted sequencing technology that performs rapid target enrichment and next generation sequencing sample preparation simultaneously$295K
- Federal grantHealth and Human S · Phase I · Target Insertion Amplification and Sequence (TIAS): A novel targeted sequencing technology that performs rapid target enrichment and next generation sequencing sample preparation simultaneously$295K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 23 peers
Line = medianMedtech · Molecule
- Federal grants#7 · top 30%
- Granted patents#5 · top 22%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 5- GrantedMethods and reagents for enhanced next generation sequencing library conversion and incorporation of molecular barcodes into targeted and random nucleic acid sequencesUSPTOUS 11,952,613
- PendingMethods And Reagents For Enhanced Next Generation Sequencing Library Conversion And Incorporation Of Molecular Barcodes Into Targeted And Random Nucleic SequencesUSPTOApplication PCTUS2020022190
- PendingMethods And Reagents For Enhanced Next Generation Sequencing Library Conversion And Incorporation Of Molecular Barcodes Into Targeted And Random Nucleic Acid SequencesUSPTOApplication 62958221
Show all 5 patent records
- Methods and reagents for enhanced next generation sequencing library conversion and incorporation of molecular barcodes into targeted and random nucleic acid sequencesApr 9, 2024 · US 11,952,613Granted
- Methods And Reagents For Enhanced Next Generation Sequencing Library Conversion And Incorporation Of Molecular Barcodes Into Targeted And Random Nucleic SequencesApplication PCTUS2020022190Pending
- Methods And Reagents For Enhanced Next Generation Sequencing Library Conversion And Incorporation Of Molecular Barcodes Into Targeted And Random Nucleic Acid SequencesApplication 62958221Pending
- Methods and Reagents for Enhanced Next Generation Sequencing Library Conversion and Incorporation of Molecular Barcodes into Targeted and Random Nucleic Acid SequencesApplication 62823519Pending
- Methods and reagents for enhanced next generation sequencing library conversion and incorporation of molecular barcodes into targeted and random nucleic acid sequencesApplication 62816231Pending
Related companies, and why
- LX MedicalSimilar federal contract value in Medtech · null in contracts
- NanoSynth Materials and Sensors Inc.Similar federal contract value in Medtech · null in contracts
- 3VO MEDICAL, INCSimilar federal contract value in Medtech · null in contracts
- PRECISION SENSING LLCSimilar federal contract value in Medtech · null in contracts
- Elekta ABSimilar federal contract value in Medtech · null in contracts
- ReValve Med, Inc.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .